Get in on Repligen Corporation’s (RGEN) buy-in window today!

Repligen Corporation (NASDAQ: RGEN) stock jumped 1.27% on Friday to $240.40 against a previous-day closing price of $237.38. With 1.13 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.51 million shares. During the session, the Medical Instruments & Supplies company that operates in wider Healthcare sector, reached to the highest price of $244.23 whereas the lowest price it dropped to was $237.29. The 52-week range on RGEN shows that it touched its highest point at $327.32 and its lowest point at $137.21 during that stretch. It currently has a 1-year price target of $236.89. Beta for the stock currently stands at 1.05.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of RGEN was up-trending over the past week, with a rise of 16.86%, but this was up by 43.37% over a month. Three-month performance surged to 48.86% while six-month performance rose 18.49%. The stock lost -3.48% in the past year, while it has lost -9.23% so far this year. A look at the trailing 12-month EPS for RGEN yields 2.52 with Next year EPS estimates of 3.47. For the next quarter, that number is 0.71. This implies an EPS growth rate of 101.50% for this year and 14.62% for next year. EPS is expected to grow by 30.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 45.60%.

Float and Shares Shorts:

At present, 55.35 million RGEN shares are outstanding with a float of 51.70 million shares on hand for trading. On Jul 14, 2022, short shares totaled 3.15 million, which was 5.68% higher than short shares on Jun 14, 2022. In addition to Mr. Anthony J. Hunt as the firm’s Pres, CEO & Director, Mr. Jon K. Snodgres serves as its Chief Financial Officer.

Institutional Ownership:

Through their ownership of 89.22% of RGEN’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 58.56% of RGEN, in contrast to 30.18% held by mutual funds. Shares owned by individuals account for 17.59%. As the largest shareholder in RGEN with 8.70% of the stake, The Vanguard Group, Inc. holds 4,819,672 shares worth 4,819,672. A second-largest stockholder of RGEN, BlackRock Fund Advisors, holds 4,564,353 shares, controlling over 8.23% of the firm’s shares. T. Rowe Price Associates, Inc. is the third largest shareholder in RGEN, holding 3,776,104 shares or 6.81% stake. With a 6.93% stake in RGEN, the T Rowe Price New Horizons Fund is the largest stakeholder. A total of 3,840,638 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.95% of RGEN stock, is the second-largest Mutual Fund holder. It holds 1,634,437 shares valued at 265.43 million. iShares Core S&P Mid Cap ETF holds 2.68% of the stake in RGEN, owning 1,486,754 shares worth 241.45 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for RGEN since 10 analysts follow the stock currently. There are 9 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With RGEN analysts setting a high price target of $320.00 and a low target of $170.00, the average target price over the next 12 months is $236.89. Based on these targets, RGEN could surge 33.11% to reach the target high and fall by -29.28% to reach the target low. Reaching the average price target will result in a decline of -1.46% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. RGEN will report FY 2022 earnings on 02/16/2023. Analysts have provided yearly estimates in a range of $3.16 being high and $3.07 being low. For RGEN, this leads to a yearly average estimate of $3.10. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Repligen Corporation surprised analysts by $0.20 when it reported $0.91 EPS against a consensus estimate of $0.71. The surprise factor in the prior quarter was $0.20. Based on analyst estimates, the high estimate for the next quarter is $0.75 and the low estimate is $0.66. The average estimate for the next quarter is thus $0.71.

Summary of Insider Activity:

Insiders traded RGEN stock several times over the past three months with 6 Buys and 8 Sells. In these transactions, 4,472 shares were bought while 16,474 shares were sold. The number of buy transactions has increased to 26 while that of sell transactions has risen to 92 over the past year. The total number of shares bought during that period was 108,377 while 158,549 shares were sold.

Leave a Comment

Your email address will not be published.